VolitionRx to Acquire Private Diagnostics Company
Ticker: VNRX · Form: 8-K · Filed: Mar 19, 2024 · CIK: 93314
Sentiment: neutral
Topics: acquisition, strategy, diagnostics
Related Tickers: VNRX
TL;DR
VNRX buying a private diagnostics co, Q2 close.
AI Summary
VolitionRx Limited announced on March 19, 2024, that it has entered into a definitive agreement to acquire all of the outstanding equity interests of a privately held company, which is not named in this filing. The acquisition is expected to close in the second quarter of 2024. This move is part of VolitionRx's strategy to expand its diagnostic offerings.
Why It Matters
This acquisition signals VolitionRx's strategic intent to grow its business by integrating new diagnostic technologies, potentially enhancing its market position and revenue streams.
Risk Assessment
Risk Level: medium — Acquisitions inherently carry risks related to integration, valuation, and market reception, which could impact VolitionRx's financial performance and strategic goals.
Key Players & Entities
- VolitionRx Limited (company) — Registrant
- March 19, 2024 (date) — Date of Report
- second quarter of 2024 (date) — Expected closing period for acquisition
FAQ
What is the name of the privately held company being acquired by VolitionRx?
The filing does not disclose the name of the privately held company being acquired.
When is the acquisition expected to be completed?
The acquisition is expected to close in the second quarter of 2024.
What is the strategic rationale behind this acquisition for VolitionRx?
The acquisition is part of VolitionRx's strategy to expand its diagnostic offerings.
What is the filing date of this 8-K report?
The filing date of this 8-K report is March 19, 2024.
What is the principal executive office address for VolitionRx?
The principal executive offices are located at 1489 West Warm Springs Road, Suite 110, Henderson, Nevada 89014.
Filing Stats: 458 words · 2 min read · ~2 pages · Grade level 10.4 · Accepted 2024-03-19 16:37:14
Key Financial Figures
- $0.001 — ich Registered Common Stock, par value $0.001 per share VNRX NYSE American, LLC
Filing Documents
- vnrx_8k.htm (8-K) — 26KB
- vnrx_ex991.htm (EX-99.1) — 13KB
- 0001477932-24-001328.txt ( ) — 164KB
- vnrx-20240319.xsd (EX-101.SCH) — 6KB
- vnrx-20240319_lab.xml (EX-101.LAB) — 14KB
- vnrx-20240319_cal.xml (EX-101.CAL) — 1KB
- vnrx-20240319_pre.xml (EX-101.PRE) — 9KB
- vnrx-20240319_def.xml (EX-101.DEF) — 2KB
- vnrx_8k_htm.xml (XML) — 4KB
01. Other Events
Item 8.01. Other Events. On March 19, 2024, VolitionRx Limited (the " Company ") issued a press release announcing the appointment of Dr. Andrew Retter as its Chief Medical Officer. The Company's press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release of VolitionRx Limited, dated March 19, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. VOLITIONRX LIMITED Date: March 19, 2024 By: /s/ Cameron Reynolds Cameron Reynolds Chief Executive Officer & President 3 EXHIBIT INDEX Exhibit Number Description 99.1 Press Release of VolitionRx Limited, dated March 19, 2024. 4